ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
19.884,75
-0,57%
S&P 500
5.930,85
1,09%
Dow Jones
42.840,26
1,18%
Euro vs US Dollar
1,04315
0,00%
Bitcoin
98.379,55
0,63%
Pepperstone
Advertisement
Registration Strip Icon for alerts Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Lantern Pharma Inc (LTRN)

  7. Lantern Pharma Inc (LTRN) News

LTRN

Lantern Pharma (LTRN)

Lantern Pharma Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:LTRN
DatumZeitQuelleÜberschriftSymbolFirma
09/12/202414h15Business WireLantern Pharma Announces First Patient Enrolled in Taiwan for Phase 2 HARMONIC™ Clinical Trial of LP-300 in Never-Smoker NSCLC PatientsNASDAQ:LTRNLantern Pharma Inc
03/12/202414h00Business WireLantern Pharma's Investigational Drug-Candidate, LP-184, Receives Second Fast Track Designation from FDA for Treatment of Triple Negative Breast Cancer (TNBC)NASDAQ:LTRNLantern Pharma Inc
26/11/202414h45Business WireLantern Pharma & Starlight Therapeutics Present LP-184 (STAR-001) Phase 1b Trial Design and Preclinical Data in Glioblastoma at Society for Neuro-Oncology (SNO) 2024 Highlighting Novel Synthetic LethalityNASDAQ:LTRNLantern Pharma Inc
19/11/202414h00Business WireLantern Pharma Announces First Patient Dosed in Japan for The Expansion Cohort in The Phase 2 HARMONIC™ Clinical Trial of LP-300 in Never-Smoker NSCLC PatientsNASDAQ:LTRNLantern Pharma Inc
07/11/202422h07Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:LTRNLantern Pharma Inc
07/11/202422h05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LTRNLantern Pharma Inc
07/11/202422h05Business WireLantern Pharma Reports Third Quarter 2024 Financial Results and Business UpdatesNASDAQ:LTRNLantern Pharma Inc
05/11/202414h00Business WireStarlight Therapeutics Announces Inaugural Members of Scientific Advisory BoardNASDAQ:LTRNLantern Pharma Inc
31/10/202413h00Business WireLantern Pharma to Report Third Quarter 2024 Operating & Financial Results on November 7th, 2024 at 4:30 p.m. ETNASDAQ:LTRNLantern Pharma Inc
23/10/202414h45Business WireLantern Pharma to Present at the ThinkEquity Conference in NYC on October 30, 2024NASDAQ:LTRNLantern Pharma Inc
21/10/202414h00Business WireLantern Pharma to Host & Participate in Two Public Webinars During OctoberNASDAQ:LTRNLantern Pharma Inc
15/10/202415h07Business WireLantern Pharma’s Investigational Drug-Candidate, LP-184, Receives Fast-Track Designation in Glioblastoma from the FDANASDAQ:LTRNLantern Pharma Inc
23/09/202414h00Business WireLantern Pharma Announces Three U.S. FDA Rare Pediatric Disease Designations Granted to LP-184 in Multiple Ultra Rare Children’s CancersNASDAQ:LTRNLantern Pharma Inc
08/08/202422h07Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:LTRNLantern Pharma Inc
08/08/202422h01Business WireLantern Pharma Reports Second Quarter 2024 Financial Results and Business UpdatesNASDAQ:LTRNLantern Pharma Inc
07/08/202415h31Business Wire Lantern Pharma Highlights Promising Preclinical Results of LP-184’s Synergy with Checkpoint Inhibitors & Sensitizing Tumors That are Non-Responsive to Anti-PD1 Therapy in Collaboration with MD Anderson at Immuno-Oncology Summit 2024NASDAQ:LTRNLantern Pharma Inc
05/08/202414h00Business WireLantern Pharma Announces Positive Clinical Update from Ongoing Phase 2 HARMONIC™ Clinical Trial for Never Smokers with Advanced NSCLC, Including an 86% Clinical Benefit Rate in the Initial Patient CohortNASDAQ:LTRNLantern Pharma Inc
01/08/202414h00Business WireLantern Pharma to Report Second Quarter 2024 Operating & Financial Results on August 8th, 2024 at 4:30 p.m. ETNASDAQ:LTRNLantern Pharma Inc
17/07/202422h30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LTRNLantern Pharma Inc
17/07/202422h30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LTRNLantern Pharma Inc
17/07/202422h30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LTRNLantern Pharma Inc
17/07/202422h30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LTRNLantern Pharma Inc
10/07/202414h30Business WireLantern Pharma Achieves Key Milestone Towards Development of Molecular Diagnostic for use in Oncology Clinical Trials for Patient Selection and Stratification with Drug Candidate LP-184NASDAQ:LTRNLantern Pharma Inc
17/06/202422h15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LTRNLantern Pharma Inc
12/06/202413h30Business WireLantern Pharma Receives Certificate of Patent from Japanese Patent Office (JPO) for Composition of Matter Covering Drug Candidate LP-284NASDAQ:LTRNLantern Pharma Inc
11/06/202406h16Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:LTRNLantern Pharma Inc
24/05/202422h09Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LTRNLantern Pharma Inc
24/05/202422h08Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:LTRNLantern Pharma Inc
24/05/202422h06Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:LTRNLantern Pharma Inc
13/05/202407h30Business WireOregon Therapeutics et Lantern Pharma lancent une collaboration stratégique dans le domaine de l’intelligence artificielle pour optimiser le développement du XCE853, premier candidat médicament de sa catégorie, un puissant inhibiteur...NASDAQ:LTRNLantern Pharma Inc
 Showing the most relevant articles for your search:NASDAQ:LTRN

Kürzlich von Ihnen besucht

NASDAQ
MSFT
Microsoft
FX
EURUSD
Euro vs US Dollar
TG
D7G
Nel ASA
DBI
SDXP
SDAX
TG
DBK
Deutsche Bank
CCOM
SILVER
SILVER
CCOM
US30
US 30
NASDAQ
QQQ
Invesco QQQ Trust Series 1
TG
NOV
Novo Nordisk
USOTC
DTEGY
Deutsche Telekom (QX)
AMEX
XLF
Financial Select Sector
AMEX
XLE
Energy Select Sector SPDR
CCOM
US100
US Tech 100
COIN
ADAUSD
Cardano
TG
DTE
Deutsche Telekom
TG
BAS
BASF
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten